玻玛西尼 Abemaciclib Also known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antine

赞鲁替尼 Zanubrutinib Zanubrutinib, aslo known as BGB-3111, is a potent and highly selective small molecule BTK inhibitor for the potential treatment of a variety of lymphomas.

依鲁替尼 Ibrutinib Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity

阿卡替尼 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.

康奈非尼 Encorafenib Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity.

达帕菲尼 Dabrafenib Dabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity.